Seth Harmon
Finanzdirektor/CFO bei VIRIDIAN THERAPEUTICS, INC.
Vermögen: 11 950 $ am 31.05.2024
Profil
Seth Harmon is currently the Chief Financial & Accounting Officer at Viridian Therapeutics, Inc. He previously worked as the Vice President-Finance at BioNTech US, Inc. from 2017 to 2020.
He also served as the Chief Financial Officer at BioNTech SE.
Mr. Harmon completed his undergraduate degree at Bowdoin College and holds a graduate degree in MBA from Northeastern University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2024 | 1 000 ( 0,00% ) | 11 950 $ | 31.05.2024 |
Aktive Positionen von Seth Harmon
| Unternehmen | Position | Beginn |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Finanzdirektor/CFO | 12.09.2023 |
Ehemalige bekannte Positionen von Seth Harmon
| Unternehmen | Position | Ende |
|---|---|---|
| NEON THERAPEUTICS, INC. | Corporate Officer/Principal | 01.05.2020 |
| BIONTECH SE | Finanzdirektor/CFO | - |
Ausbildung von Seth Harmon
| Northeastern University | Graduate Degree |
| Bowdoin College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| BIONTECH SE | Health Technology |
| Private Unternehmen | 1 |
|---|---|
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
